Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCR102 in SR-aGVHD
NCT06941350Phase 2Not yet recruiting
- Sponsor
- Nuwacell Biotechnologies
- Start
- Apr 2025
- Primary completion
- Oct 2026
- Modality
- Mesenchymal Stem Cells, Patient-derived iPSCs, Allogeneic iPSCs
01
Overview
Phase 2, open-label, single-arm trial of NCR102 in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Nuwacell Biotechnologies. Primary endpoint: Adverse Event or Serious Adverse Event at 100 days. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
NCR102
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT06941350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06941350.